Holen Sie sich die Stockscreener-App
34.62
0.80%
-0.28
Neurogene Inc Aktie (NGNE) Neueste Nachrichten
Neurogene Inc (NGNE) Institutional Confidence - TradingKey
NGNE|Neurogene Inc|Price:34.610|Chg%:-0.290 - TradingKey
Neurogene Inc (NGNE) Cash Flow - TradingKey
Neurogene Inc (NGNE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neurogene Inc (NGNE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neurogene Inc (NGNE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ETFs Investing in Neurogene Inc. Stocks - TradingView
TradingKey - TradingKey
Neurogene Inc (NGNE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Neurogene Completes $143.7 Million Public Offering of Shares and Pre-Funded Warrants - Global Legal Chronicle
Neurogene prices $125M equity offering - MSN
Neurogene Inc. (NGNE) Q1 2026 Earnings: EPS Miss and No Revenue Highlight Pre-Commercial Challenges - dars.gov.et
This $20 Biotech Stock Just Got An FDA Boost – And A $200 Price Target - Stocktwits
Neurogene Advances Pivotal Gene Therapy Trial, Embodying Houston's Dynamic Life Sciences Ecosystem - Greater Houston Partnership
LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Neurogene Surges To A New 52-Week High: Will NGN-401 Reshape The Rett Syndrome Market? - RTTNews
Rett gene therapy drives lasting developmental gains: Long-term data - Rett Syndrome News
Neurogene president & CFO Cvijic sells $173,375 in stock - Investing.com
Insider Sell: Christine Cvijic Sells 4,800 Shares of Neurogene I - GuruFocus
Neurogene president & CFO Cvijic sells $173,375 in stock By Investing.com - Investing.com Nigeria
Form 4 Neurogene Inc For: 7 July By Investing.com - Investing.com Nigeria
Neurogene (NGNE) CFO sells 4,800 shares and retains 84,040 including RSUs - Stock Titan
A Quick Look at Today's Ratings for Neurogene(NGNE.US), With a Forecast Between $60 to $180 - Moomoo
LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Raises Target Price to $65 - Moomoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Neurogene lures 6 new hires with stock options tied to July 6 close - Stock Titan
Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Enterprise value to revenue forward of Neurogene Inc. – NASDAQ:NGNE - TradingView
Neurogene announces pricing of $125 million public offering - The Pharma Letter
Neurogene president and CFO Cvijic sells $166,586 of company stock By Investing.com - Investing.com South Africa
Neurogene president and CFO Cvijic sells $166,586 of company stock - Investing.com
Form 4 Neurogene Inc For: 2 July By Investing.com - Investing.com Canada
Neurogene (NGNE) CFO’s 4,800-share sale under 10b5-1 plan - Stock Titan
Neurogene: 'Hold' EMBOLDEN Study Underway And 2nd Half 2027 Topline Data - Seeking Alpha
Form 424B5 Neurogene Inc For: 2 July By Investing.com - Investing.com Canada
Neurogene Nets ~$135 Million From Equity Offering; Underwriters Exercise Full Option - TradingView
Neurogene (NGNE) secures $134.8M, extending cash runway into 2029 - Stock Titan
Citizens reiterates Taysha Gene Therapies stock rating on therapy progress By Investing.com - Investing.com Canada
Citizens reiterates Taysha Gene Therapies stock rating on therapy progress - Investing.com
Neurogene bolsters cash runway with equity offering - TipRanks
Leerink raises Neurogene stock price target to $77 on Rett data By Investing.com - Investing.com South Africa
Neurogene (NGNE) sells 3.5M shares, pre-funded warrants in $117M deal - Stock Titan
Leerink raises Neurogene stock price target to $77 on Rett data - Investing.com Nigeria
Neurogene Inc. Stock 12‑Month Price Target Raised to $79.62, Implies 153% Upside - TradingView
Neurogene prices $125 million public offering at $30 per share By Investing.com - Investing.com Australia
Neurogene prices $125 million public offering at $30 per share - Investing.com
Neurogene Sets Pricing For $125 Million Public Offering - TradingView
Why is Neurogene stock sliding today? By Investing.com - Investing.com Canada
Neurogene Prices $125 Million Public Offering - marketscreener.com
Neurogene locks in $125M stock sale, closing expected July 2 - Stock Titan
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):